Highlights of ACC 2024
Cardiology Update
APRIL 9, 2024
EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). Here is our curated list of the top sessions.
Let's personalize your content